Ionis Pharmaceuticals Inc (ISI)

25.750
+2.370(+10.14%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    25.750 - 25.750
  • Type:Equity
  • Market:Germany
  • ISIN:US4622221004
  • WKN:A2ACMZ

ISI Overview

Prev. Close
23.38
Day's Range
25.75-25.75
Revenue
-
Open
25.75
52 wk Range
22.37-52.43
EPS
0.11
Volume
0
Market Cap
3.83B
Dividend (Yield)
0.00
(N/A)
Average Vol. (3m)
490
P/E Ratio
520.61
Beta
1.79
1-Year Change
-44.14%
Shares Outstanding
141,210,015
Next Earnings Date
-
What is your sentiment on Ionis Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Ionis Pharmaceuticals Inc Company Profile

Employees
757

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington’s diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson’s disease; ION464 for multiple system atrophy and Parkinson’s disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralNeutralSellStrong Sell
Technical IndicatorsBuyBuyBuySellStrong Sell
SummaryNeutralNeutralNeutralSellStrong Sell
  • What’s about this stock? Any new therapies are coming out?
    0
    • I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
      0
  • Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
    0
    • Added 4000 at 34.4
      1
      • nice after market move!
        0
        • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
          0
          • CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
            0
            • this stock doesn't know what a green day looks like.
              0
              • ㅜㅜ~
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.